The webinar generated a lot of interest with many people in attendance; but if you missed out, a recording of the webinar is available above.
Jon Tinsley (Chief Scientific Officer) and Ann Heatherington (Head of Clinical Development) from Summit, were kind enough to talk us through their results to date.
Action Duchenne, PPMD and Summit Therapeutics have worked together to bring you a handy FAQ document to help explain things as well.
Thank you to PPMD and Summit Therapeutics for their help.
Like most websites we use cookies to deliver a personalised service. To use the website as intended please accept cookies.
Privacy & Cookies Policy
Privacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
Catabasis reports Edsalonexent preserved muscle function and slowed progression of Duchenne through more than one year of treatment
